3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
6
aldesleukin
6
Cyclophosphamide
6
fludarabine phosphate
5
fludarabine
5
Nivolumab
4
durvalumab
3
Sorafenib
3
Radiotherapy
3
Filgrastim
3
Everolimus
3
Axitinib
3
Temozolomide
2
Peripheral Blood Stem Cell Transplantation
2
Isotretinoin
2
Ipilimumab
2
Interleukin-2
2
Interferon-alpha
2
Fluorouracil
2
Dexamethasone
2
Cyclosporine
2
Bevacizumab
2
vorolanib
1
tremelimumab
1
tocilizumab
1
talazoparib
1
spartalizumab
1
sargramostim
1
poly ICLC
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Kidney Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled